proxyvotesnow.com

Home › Companies › Adaptive Biotechnologies Corporation › 2025-2026

Adaptive Biotechnologies Corporation 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 02 October 2026.

  • 6Reported items
  • 319Asset managers
  • 1,517Fund votes
  • 2026-06-05Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Adaptive Biotechnologies Corporation in the interactive database Compare manager voting policies

How asset managers voted at the Adaptive Biotechnologies Corporation 2025-2026 meeting

Each item below shows how the 319 asset managers that disclosed a Adaptive Biotechnologies Corporation vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Adaptive Biotechnologies Corporation’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 307 asset managers below cast 98% of the shares they voted on this item FOR (144,542,766 for, 3,500,010 against).

FOR: 144,542,766 (97.6%)AGAINST: 3,500,010 (2.4%)ABSTAIN: 91,803 (0.1%)NOT VOTED: 32 (0.0%)
Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in ” at Adaptive Biotechnologies Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
VIKING GLOBAL INVESTORS LP29,993,7080 00For
BlackRock12,065,5042,375 00For
Vanguard11,569,5539 00For
Invesco6,553,8370 00For
WESTFIELD CAPITAL MANAGEMENT CO LP4,994,0480 00For
T. Rowe Price4,461,8560 00For
Fidelity4,360,4530 00For
GEODE CAPITAL MANAGEMENT, LLC3,643,3180 00For
Wellington3,113,2670 00For
LORD, ABBETT & CO. LLC2,872,9640 00For
State Street2,853,4054,618 00For
Columbia Threadneedle2,671,6430 00For
BNP Paribas Asset Management Holding S.A.02,572,254 00Against
Charles Schwab2,264,1160 00For
Goldman Sachs2,205,5640 00For
FRED ALGER MANAGEMENT, LLC2,109,3300 00For
Lord Abbett2,081,6680 00For
ARK ETF Trust1,987,5100 00For
ALGER FUNDS1,724,4970 00For
Amova Asset Management Co., Ltd.1,591,6270 00For
Nuveen1,554,3850 00For
TIAA1,536,7170 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST1,472,3930 00For
Aristotle Atlantic Partners, LLC1,298,1930 00For
DRIEHAUS CAPITAL MANAGEMENT LLC1,267,0130 00For

Showing the 25 largest of 307 asset managers. See all 307 in the interactive database.

2. To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2029 annual meeting of shareholders: Katey Owen, PhD

DIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99%

The 98 asset managers below cast 100% of the shares they voted on this item FOR (50,610,991 for, 0 against).

FOR: 50,610,991 (98.9%)ABSTAIN: 564,241 (1.1%)
Largest asset managers voting on “To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporat” at Adaptive Biotechnologies Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,495,4750 10,0730For
BlackRock6,627,9730 00For
Fidelity3,795,5860 00For
Columbia Threadneedle2,671,6430 00For
Invesco2,516,3210 00For
Lord Abbett2,081,6680 00For
ARK ETF Trust1,987,5100 00For
T. Rowe Price1,797,3110 00For
ALGER FUNDS1,724,4970 00For
TIAA1,536,7170 00For
HARBOR FUNDS1,145,0000 00For
Charles Schwab1,131,6150 00For
MFS1,072,5050 00For
Waddell & Reed1,008,5960 00For
OBERWEIS FUNDS774,6000 00For
Aristotle Funds Series Trust687,2600 00For
Principal555,3060 00For
First Trust553,2180 00For
Goldman Sachs534,3820 00For
Hartford531,4560 00For
Jackson National491,4100 3,5250For
Equitable471,2340 00For
Brighthouse435,1900 15,0220For
OPTIMUM FUND TRUST407,1970 00For
MassMutual332,9360 00For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

3. To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2029 annual meeting of shareholders: Robert Hershberg, PhD, MD

DIRECTOR ELECTIONS

Combines 5 wordings of this item as funds reported it.

100% fund support · no official result

FOR 73%ABSTAIN 27%

The 98 asset managers below cast 100% of the shares they voted on this item FOR (37,187,617 for, 0 against).

FOR: 37,187,617 (72.7%)ABSTAIN: 13,987,615 (27.3%)
Largest asset managers voting on “To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporat” at Adaptive Biotechnologies Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,495,4000 10,1480For
BlackRock6,627,9730 00For
Fidelity3,791,8470 3,7390For
Columbia Threadneedle2,671,6430 00For
Invesco2,516,3210 00For
Lord Abbett2,081,6680 00For
ARK ETF Trust1,987,5100 00For
T. Rowe Price1,138,9580 658,3530For
ALGER FUNDS00 1,724,4970Abstain
TIAA00 1,536,7170Abstain
HARBOR FUNDS00 1,145,0000Abstain
Charles Schwab1,131,6150 00For
MFS00 1,072,5050Abstain
Waddell & Reed00 1,008,5960Abstain
OBERWEIS FUNDS00 774,6000Abstain
Aristotle Funds Series Trust00 687,2600Abstain
Principal00 555,3060Abstain
First Trust00 553,2180Abstain
Goldman Sachs491,6920 42,6900For
Hartford531,4560 00For
Jackson National491,4100 3,5250For
Equitable393,3740 77,8600For
Brighthouse383,0220 67,1900For
OPTIMUM FUND TRUST158,6320 248,5650Abstain
MassMutual332,9360 00For

Showing the 25 largest of 98 asset managers. See all 98 in the interactive database.

4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2026; and

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% fund support · no official result

FOR 99.9%

The 96 asset managers below cast 99.9% of the shares they voted on this item FOR (50,895,398 for, 1 against).

FOR: 50,895,398 (100.0%)AGAINST: 1 (0.0%)ABSTAIN: 15,022 (0.0%)
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the ye” at Adaptive Biotechnologies Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard10,505,5461 00For
BlackRock6,627,9730 00For
Fidelity3,795,5860 00For
Columbia Threadneedle2,671,6430 00For
Invesco2,516,3210 00For
Lord Abbett2,081,6680 00For
ARK ETF Trust1,987,5100 00For
T. Rowe Price1,797,3110 00For
ALGER FUNDS1,724,4970 00For
TIAA1,536,7170 00For
HARBOR FUNDS1,145,0000 00For
Charles Schwab1,131,6150 00For
MFS1,072,5050 00For
Waddell & Reed1,008,5960 00For
OBERWEIS FUNDS774,6000 00For
Aristotle Funds Series Trust687,2600 00For
Principal555,3060 00For
First Trust553,2180 00For
Goldman Sachs534,3820 00For
Hartford531,4560 00For
Jackson National494,9350 00For
Equitable471,2340 00For
OPTIMUM FUND TRUST407,1970 00For
MassMutual332,9360 00For
NORTHERN LIGHTS FUND TRUST III311,5640 00For

Showing the 25 largest of 96 asset managers. See all 96 in the interactive database.

5. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 9 asset managers below cast 100% of the shares they voted on this item FOR (427,478 for, 0 against).

FOR: 427,478 (100.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Adaptive Biotechnologies Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Brighthouse237,8700 00For
ALGERT GLOBAL LLC109,5050 00For
Integrated Quantitative Investments LLC18,1500 00For
APG Asset Management US Inc.14,8500 00For
FORUM FUNDS II14,1330 00For
Vinva Investment Management Ltd13,3580 00For
CLEARWATER INVESTMENT TRUST12,8070 00For
Wilshire Advisors LLC5,1050 00For
Convergence Investment Partners, LLC1,7000 00For

6. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (264,810 for, 0 against).

FOR: 264,810 (100.0%)
Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at Adaptive Biotechnologies Corporation, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Brighthouse237,8700 00For
FORUM FUNDS II14,1330 00For
CLEARWATER INVESTMENT TRUST12,8070 00For

Largest Adaptive Biotechnologies Corporation shareholders voting in 2025-2026

Ranked by the number of Adaptive Biotechnologies Corporation shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 159,697,221 shares outstanding at the time of that meeting.

Top Adaptive Biotechnologies Corporation shareholders by shares voted, 2025-2026
#Asset manager % of shares outstanding
1VIKING GLOBAL INVESTORS LP 18.78%
2BlackRock 7.56%
3Vanguard 7.24%
4Invesco 4.10%
5WESTFIELD CAPITAL MANAGEMENT CO LP 3.13%
6T. Rowe Price 2.79%
7Fidelity 2.73%
8GEODE CAPITAL MANAGEMENT, LLC 2.28%
9Wellington 1.95%
10LORD, ABBETT & CO. LLC 1.80%

Reported Adaptive Biotechnologies Corporation ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Adaptive Biotechnologies Corporation beneficial owners on record for the 2025-2026 proxy season
Holder % outstanding Disclosure
VIKING GLOBAL INVESTORS LP 18.78% 13G
Viking Global Entities 18.78% DEF14A
BlackRock 8.33% 13F
Vanguard Subsidiaries and Divisions 6.66% DEF14A
Invesco 2.79% 13F
Wellington Management 2.42% 13F
Geode Capital 2.28% 13F
Goldman Sachs 2.03% 13F
State Street 2.02% 13F
Chad Robins 1.96% DEF14A

Percentages above are of 159,697,221 shares outstanding, as reported by Adaptive Biotechnologies Corporation on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Adaptive Biotechnologies Corporation’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Adaptive Biotechnologies Corporation's shareholder meeting held 2026-06-05, in the 2025-2026 proxy season, 319 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,517 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Adaptive Biotechnologies Corporation proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).